1. Search Result
Search Result
Results for "

5-LOX Inhibitor

" in MedChemExpress (MCE) Product Catalog:

63

Inhibitors & Agonists

15

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-138939

    Lipoxygenase Cancer
    5-LOX-IN-2, an inhibitor of 5-lipoxygenase (5-LOX) with an IC50 of 0.33 μM, inhibits 5-LOX in a dose-dependent manner . 5-LOX-IN-2, reduces the cell viability of renal cancer cells and induces apoptosis, can be used for cancer research .
    5-LOX-IN-2
  • HY-W009671

    Lipoxygenase Cancer
    3-Chloroiminodibenzyl (compound 8) is a dual inhibitor of sHE and 5-LOX. 3-Chloroiminodibenzyl inhibits sHE and 5-LOX with IC50 of 140 μM and 6.5 μM, respectively .
    3-Chloroiminodibenzyl
  • HY-117048

    PF-04191834

    Lipoxygenase Inflammation/Immunology
    PF-4191834 (PF-04191834) is an orally active, noniron chelating, and non-redox inhibitor of the 5-Lipoxygenase (5-LOX) (IC50=229 nM), displays ~300-fold selectivity for 5-LOX over 12-LOX and 15-LOX, shows no activity toward the cyclooxygenase enzymes, and is effective in inflammation and pain .
    PF-4191834
  • HY-148134

    Lipoxygenase Inflammation/Immunology
    5-LOX-IN-1 (compound 2b) is an inhibitor of human 5-Lipoxygenase (5-LOX) with an IC50 value of 2.3 μM. 5-LOX-IN-1 can be used for the research of inflammation .
    5-LOX-IN-1
  • HY-113807

    COX Lipoxygenase Inflammation/Immunology
    ZLJ-6 is a dual COX and 5-LOX inhibitor with oral activity. The IC50 values for COX-1, COX-2 and 5-LOX were 0.73, 0.31 and 0.99 μM, respectively. ZLJ-6 has anti-inflammatory and analgesic activity .
    ZLJ-6
  • HY-170957

    Lipoxygenase NO Synthase Inflammation/Immunology
    5-LOX/NO-IN-1 (Compound 7e) is a 5-LOX and NO release inhibitor. 5-LOX/NO-IN-1 shows an IC50 of 2.833 μM for 5-LOX. 5-LOX/NO-IN-1 has anti-inflammatory effects .
    5-LOX/NO-IN-1
  • HY-155407

    FLAP Inflammation/Immunology
    ALR-6 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-6 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM and has no significant effect on direct inhibition of 5-LOX .
    ALR-6
  • HY-149476

    Lipoxygenase Neurological Disease
    5-LOX-IN-5 (Compound 29) is a 5-LOX inhibitor (IC50: 56 nM). 5-LOX-IN-5 can be used for research of neurodegenerative diseases .
    5-LOX-IN-5
  • HY-155408

    FLAP Inflammation/Immunology
    ALR-27 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-27 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM, with no significant direct inhibition of 5-LOX. ALR-27 not only reduces prostaglandin and leukotriene (LT) production in neutrophils but also increases the production of specialized prolytic mediators in specific human macrophage phenotypes .
    ALR-27
  • HY-133215

    Lipoxygenase Inflammation/Immunology
    Zileuton sulfoxide is a sulfoxide derivative of Zileuton (HY-14164), a potent and selective inhibitor of lipoxygenase 5-LOX with anti-asthmatic properties .
    Zileuton sulfoxide
  • HY-173056

    Lipoxygenase Inflammation/Immunology
    Ruthenoleuton is a 5-lipoxygenase (5-LOX) inhibitor with an IC50 of 3.49 μM and a Ki of 0.80 μM. Ruthenoleuton has antioxidant activity and can be used in the research of inflammatory diseases .
    Ruthenoleuton
  • HY-116763

    COX LOX-1
    COX-2/5-LOX-IN-4 (Compound 1) is a dual inhibitor that acts on both COX-2 and 5-LOX, with IC50 values of 0.05 μM for COX-2 and 0.003 μM for 5-LOX. By inhibiting the arachidonic acid metabolism pathway, COX-2/5-LOX-IN-4 reduces the production of prostaglandins and leukotrienes, alleviating inflammatory responses. In a rat ear edema model, intravenous administration (0.01 and 0.1 mg/kg) reduced edema by 41% and 44%, respectively, demonstrating significant anti-inflammatory effects. COX-2/5-LOX-IN-4 shows promise for studying the mechanisms of inflammatory diseases .
    COX-2/5-LOX-IN-4
  • HY-N0198
    Nordihydroguaiaretic acid
    5+ Cited Publications

    NDGA

    Lipoxygenase Autophagy Ferroptosis Neurological Disease Cancer
    Nordihydroguaiaretic acid is a 5-lipoxygenase (5LOX) (IC50=8 μM) and tyrosine kinase inhibitor.
    Nordihydroguaiaretic acid
  • HY-155409

    Lipoxygenase Inflammation/Immunology
    ALR-38 is a 5-lipoxygenase (5-LOX) inhibitor (IC50: 1.1 μM) with anti-inflammatory activity. ALR-38 effectively reduces ROS levels in neutrophils .
    ALR-38
  • HY-163736

    Lipoxygenase PGE synthase Inflammation/Immunology
    mPGES-1/5-LOX-IN-1 (compound 3j) is a potent and orally active mPGES-1 and 5-LOX dual inhibitor with IC50 values of 0.92, 1.89 µM, respectively. mPGES-1/5-LOX-IN-1 shows anti-inflammatory impact .
    mPGES-1/5-LOX-IN-1
  • HY-147951

    COX Lipoxygenase Inflammation/Immunology
    COX-2/5-LOX-IN-3 (compound 5b) is a potent and dual COX-2/5-LOX inhibitor with IC50 values of 45.73, 5.45 and 4.33 μM for COX-1, COX-2, and 5-LOX, respectively. COX-2/5-LOX-IN-3 has the potential for the research of inflammation diseases .
    COX-2/5-LOX-IN-3
  • HY-173180

    Lipoxygenase Interleukin Related TNF Receptor IFNAR Inflammation/Immunology
    5-LOX-IN-8 is a 5-LOX inhibitor with anti-inflammatory activity. 5-LOX-IN-8 suppresses IL-6, IL-1β, TNF-α and IFN-γ in macrophages and reduces IL-8 secretion in SW480 cells. 5-LOX-IN-8 reduces disease activity in a DSS colitis model. 5-LOX-IN-8 can be used for research of inflammatory bowel disease (IBD) .
    5-LOX-IN-8
  • HY-118268

    Lipoxygenase Cardiovascular Disease
    RG 6866 is a 5-lipoxygenase (5-LOX) inhibitor with the potential to inhibit coronary artery constriction and negative cardiac inotropic effects in cardiac inflammatory states. When the heart is stimulated by antigens, RG 6866 can block the antigen-induced reduction in coronary flow in the heart.
    RG 6866
  • HY-158204

    Lipoxygenase Amyloid-β Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology
    CNB-001 is a potent and orally active 5-lipoxygenase (5-LOX) inhibitor. CNB-001 can decreases 5-LOX expression and increase proteasome activity. CNB-001 can inhibit accumulation of soluble Amyloid-β and ubiquitinated aggregated proteins. CNB-001 can inhibit apoptosis, ROS production and stabilize mitochondrial membrane potential. CNB-001 can reduce insulin resistance and increase glucose uptake. CNB-001 also exhibits anti-ischemic, anti-inflammatory effects. CNB-001 can be used for the researches of inflammation, neurological and metabolic disease, such as Alzheimer's disease, stroke and diabetes .
    CNB-001
  • HY-N0232
    Psoralidin
    4 Publications Verification

    COX Lipoxygenase Notch Reactive Oxygen Species (ROS) Bacterial Cancer
    Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties . Psoralidin significantly downregulates NOTCH1 signaling. Psoralidin also greatly induces ROS generation .
    Psoralidin
  • HY-10439

    PGE synthase Inflammation/Immunology
    HPGDS inhibitor 1 is a potent, selective and orally active Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX .
    HPGDS inhibitor 1
  • HY-114796

    Lipoxygenase Inflammation/Immunology
    tHGA is a compound with anti-inflammatory activity and has the activity to inhibit soybean 15-LOX. tHGA showed significant inhibitory effects in experiments on human leukocytes, with an IC50 value of 0.42 μM, which is close to the effect of commonly used standard NDGA. tHGA concentration-dependently inhibits the synthesis of 5-LOX products, especially the cysteine leukotriene LTC(4), with an IC50 value of 1.80 μM. and showed no cytotoxicity. The anti-inflammatory effects of tHGA do not appear to be through redox or metal chelation mechanisms, as the compound was negative in these bioactivity tests. tHGA works through a dual LOX/COX inhibition mechanism and has higher selectivity for 5-LOX and COX-2, with an IC50 value of 0.40 μM .
    tHGA
  • HY-121585

    Lipoxygenase Inflammation/Immunology
    CAY10698 (compound 1) is a potent and selective inhibitor of 12-Lipoxygenase (12-LOX) with an IC50 of 5.1 μM. CAY10698 is inactive against 5-LOX, 15-LOX-1, 15-LOX-2 and COX-1/2 .
    CAY10698
  • HY-106835

    VUFB 16066

    COX Lipoxygenase Inflammation/Immunology
    Flobufen (VUFB 16066) is a non-steroidal anti-inflammatory agent and cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibitor agent. Flobufen inhibits alloantigen-driven cellular immune responses and stimulates phagocytosis of peritoneal cells. Flobufen can improve immunopathological disorders and has an inhibitory effect on rheumatoid arthritis .
    Flobufen
  • HY-N0198R

    NDGA (Standard)

    Reference Standards Lipoxygenase Autophagy Ferroptosis Neurological Disease Cancer
    Nordihydroguaiaretic acid (Standard) is the analytical standard of Nordihydroguaiaretic acid. This product is intended for research and analytical applications. Nordihydroguaiaretic acid is a 5-lipoxygenase (5LOX) (IC50=8 μM) and tyrosine kinase inhibitor.
    Nordihydroguaiaretic acid (Standard)
  • HY-156329

    Epoxide Hydrolase FLAP Inflammation/Immunology
    sEH/FLAP-IN-1 (Compound 46A) is a sEH/FLAP inhibitor. sEH/FLAP-IN-1 inhibits 5-LOX product formation in SACM-stimulated PBMCs (EC50: 11 nM). sEH/FLAP-IN-1 inhibit sEH (EC50: 18 nM) and thromboxane production. sEH/FLAP-IN-1 can be used for research of inflammatory diseases .
    sEH/FLAP-IN-1
  • HY-162523

    Monoamine Oxidase Cholinesterase (ChE) COX Lipoxygenase Neurological Disease
    hMAO-B-IN-8 (Compound 23) is a hMAO-B, eeAChE, COX-2 and 5-LOX inhibitor, with IC50 values of 0.037 μM, 0.071 μM, 14.3 μM and 0.59 μM, respectively. hMAO-B-IN-8 can be used for the research of Alzheimer's disease .
    hMAO-B-IN-8
  • HY-105024

    Lipoxygenase COX Inflammation/Immunology
    FPL 62064 is a potent 5-lipoxygenase (5-LOX) and COX dual inhibitor, with IC50 values of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and prostaglandin synthetase (cyclooxygenase), respectively. FPL 62064 has potent anti-inflammatory activity .
    FPL 62064
  • HY-B1452
    Licofelone
    1 Publications Verification

    ML-3000

    COX Lipoxygenase Apoptosis Inflammation/Immunology Cancer
    Licofelone (ML-3000) is a dual COX/5-lipoxygenase (5-LOX) inhibitor (IC50=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects. Licofelone induces apoptosis, and decreases the production of proinflammatory leukotrienes and prostaglandins .
    Licofelone
  • HY-A0060

    NKK 105

    Lipoxygenase Cancer
    Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes .
    Malotilate
  • HY-146295

    COX Inflammation/Immunology
    COX-2/5-LOX-IN-2 (5b) is a potent and dual inhibitor of COX-2/5-LOX. COX-2/5-LOX-IN-2 is a benzothiophen-2-yl pyrazole carboxylic acid derivative. COX-2/5-LOX-IN-2 shows the most potent analgesic and anti-inflammatory activities surpassing that of Celecoxib and Indomethacin. COX-2/5-LOX-IN-2 shows potent COX-1, COX-2 and 5-LOX inhibitory activity with IC50s of 5.40, 0.01 and 1.78 μM, respectively .
    COX-2/5-LOX-IN-2
  • HY-146294

    COX Inflammation/Immunology
    COX-2/5-LOX-IN-1 (compound 3a) is a potent and dual inhibitor of COX-2/5-LOX. COX-2/5-LOX-IN-1 is a benzothiophen-2-yl pyrazole carboxylic acid derivative. COX-2/5-LOX-IN-1 shows the most potent analgesic and anti-inflammatory activities surpassing that of Celecoxib and Indomethacin. COX-2/5-LOX-IN-1 shows potent COX-1, COX-2 and 5-LOX inhibitory activity with IC50s of 12.13, 0.4 and 4.96 μM, respectively .
    COX-2/5-LOX-IN-1
  • HY-118848

    Lipoxygenase Leukotriene Receptor Inflammation/Immunology
    A63162 is a specific 5-lipoxygenase (5-LOX) inhibitor. A63162 inhibits mitogen (PHA)-induced horse mononuclear cell (BMC) proliferation and inhibits Calcimycin (HY-N6687)-induced leukotriene LTB4 synthesis at the same concentration. A63162 can be used in the study of chronic obstructive pulmonary disease, arthritis and inflammatory bowel disease .
    A63162
  • HY-172790

    COX Lipoxygenase Inflammation/Immunology
    Cbz-(S,S)-Pro-Pro-allyl (compound 1a) is a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase with IC50 values of 0.146 nM, 0.003 nM, 0.64 nM for COX-1, COX-2, 5-LOX, respectively. Cbz-(S,S)-Pro-Pro-allyl has anti-inflammatory activity .
    Cbz-(S,S)-Pro-Pro-allyl
  • HY-N0232R

    Reference Standards COX Lipoxygenase Notch Reactive Oxygen Species (ROS) Bacterial Cancer
    Psoralidin (Standard) is the analytical standard of Psoralidin. This product is intended for research and analytical applications. Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties . Psoralidin significantly downregulates NOTCH1 signaling. Psoralidin also greatly induces ROS generation .
    Psoralidin (Standard)
  • HY-128171
    Diflapolin
    1 Publications Verification

    FLAP Epoxide Hydrolase Inflammation/Immunology
    Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC50s?of? 30 and 170?nM, respectively, and suppressed the activity of isolated sEH (IC50=20?nM) .
    Diflapolin
  • HY-N0551
    Wedelolactone
    Maximum Cited Publications
    22 Publications Verification

    Caspase Lipoxygenase Apoptosis Inflammation/Immunology Cancer
    Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibits the IKK Complex. Wedelolactone also inhibits 5-lipoxygenase (5-Lox) with an IC50 of 2.5 μM. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Wedelolactone can extract from Eclipta alba, and it can be used for the research of cancer .
    Wedelolactone
  • HY-B1452S1

    ML-3000-d6

    Apoptosis Lipoxygenase COX Cancer
    Licofelone-d6 is the deuterium labeled Licofelone . Licofelone (ML-3000) is a dual COX/5-lipoxygenase (5-LOX) inhibitor (IC50=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects. Licofelone induces apoptosis, and decreases the production of proinflammatory leukotrienes and prostaglandins .
    Licofelone-d6
  • HY-114873

    LY25684

    Phospholipase COX Lipoxygenase Leukotriene Receptor Inflammation/Immunology
    LY256548 (LY25648) is an orally available anti-ischemic and anti-inflammatory compound with central nervous system activity. LY256548 is an inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and COX, and inhibits A23187 (HY-N6687)-stimulated leukotriene B4 production. LY256548 inhibits bone damage and paw swelling in the rat Freund's complete adjuvant-induced arthritis (FCA) model .
    LY256548
  • HY-A0060R

    Lipoxygenase Cancer
    Malotilate (Standard) is the analytical standard of Malotilate. This product is intended for research and analytical applications. Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes .
    Malotilate (Standard)
  • HY-B1452R

    COX Lipoxygenase Apoptosis Inflammation/Immunology Cancer
    Licofelone (Standard) is the analytical standard of Licofelone. This product is intended for research and analytical applications. Licofelone (ML-3000) is a dual COX/5-lipoxygenase (5-LOX) inhibitor (IC50=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects. Licofelone induces apoptosis, and decreases the production of proinflammatory leukotrienes and prostaglandins .
    Licofelone (Standard)
  • HY-149270

    COX Inflammation/Immunology
    COX-2-IN-31 (compound 7b) is an orally active and dual inhibitor of COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM). COX-2-IN-31 also inhibits transmembrane hCA IX(Ki=48.9 nM) and hCA XII(Ki=5.8 nM) activity. COX-2-IN-31 exhibits anti-inflammatory and analgesic activity .
    COX-2-IN-31
  • HY-N0551R

    Reference Standards Caspase Lipoxygenase Apoptosis Inflammation/Immunology Cancer
    Wedelolactone (Standard) is the analytical standard of Wedelolactone. This product is intended for research and analytical applications. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibits the IKK Complex. Wedelolactone also inhibits 5-lipoxygenase (5-Lox) with an IC50 of 2.5 μM. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Wedelolactone can extract from Eclipta alba, and it can be used for the research of cancer .
    Wedelolactone (Standard)
  • HY-N2056

    11-Keto-β-boswellic acid

    Lipoxygenase Leukotriene Receptor NF-κB Metabolic Disease Cancer
    11-Keto-beta-boswellic acid (11-Keto-β-boswellic acid) is a pentacyclic triterpenic acid of the oleogum resin from the bark of the Boswellia serrate tree, popularly known as Indian Frankincense. 11-Keto-beta-boswellic acid has the anti-inflammatory activity is primarily due to inhibit 5-lipoxygenase (5-LOX) and subsequent leukotriene and nuclear factor-kappa B (NF-κB) activation and tumor necrosis factor alpha generation production .
    11-​Keto-​beta-​boswellic acid
  • HY-N1942
    5-O-Demethylnobiletin
    2 Publications Verification

    5-Demethylnobiletin

    Lipoxygenase Leukotriene Receptor Neurological Disease Inflammation/Immunology Cancer
    5-O-Demethylnobiletin (5-Demethylnobiletin), a polymethoxyflavone isolated from Citrus jambhiri Lush., is a direct inhibition of 5-LOX (IC50=0.1 μM), without affecting the expression of COX-2. 5-O-Demethylnobiletin (5-Demethylnobiletin) has anti-inflammatory activity, inhibits leukotriene B (4)(LTB4) formation in rat neutrophils and elastase release in human neutrophils with an IC50 of 0.35 μM .
    5-O-Demethylnobiletin
  • HY-125975

    Lipoxygenase Inflammation/Immunology
    1-Naphthyl 3,5-dinitrobenzoate is a potent 5-lipoxygenase inhibitor with IC50 values of 1.04 µM and 3.6 µM for 5-LOX and mPGES-1, respectively. 1-Naphthyl 3,5-dinitrobenzoate has strong inhibition activity in the human whole blood (HWB) assay with an IC50 value of 8.6 μM. 1-Naphthyl 3,5-dinitrobenzoate can be used in research of inflammation .
    1-Naphthyl 3,5-dinitrobenzoate
  • HY-N7108
    7-Hydroxyflavone
    1 Publications Verification

    ERK Keap1-Nrf2 Apoptosis COX Pyruvate Kinase Lipoxygenase Enterovirus Virus Protease Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    7-Hydroxyflavone is a flavonoid isolated from Clerodendrum phlomidis, with anti-inflammatory activity. 7-Hydroxyflavone protects renal cells from nicotine (NIC)-associated cytotoxicity via the ERK/Nrf2/HO-1 pathway. 7-Hydroxyflavone inhibits PKM2 with an IC50 of 2.12 μM. 7-Hydroxyflavone inhibits COX-2 and 5-LOX with IC50 of 27 µg/mL and 33 µg/mL. 7-Hydroxyflavone is orally active .
    7-Hydroxyflavone
  • HY-111310
    ML351
    1 Publications Verification

    Lipoxygenase Neurological Disease Metabolic Disease
    ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC50 of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2 . ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D .
    ML351
  • HY-149269

    COX Carbonic Anhydrase LOX-1 Inflammation/Immunology
    COX-2-IN-30 is a benzenesulfonamide derivative, as well as an orally active and dual inhibitor of COX (IC50=49 nM for COX-2, 10.4 μM for COX-1) and 5-LOX (IC50=2.4 μM). COX-2-IN-30 also inhibits transmembrane hCA IX and hCA XII isoform with nanomolar calss Ki values. COX-2-IN-30 exhibits analgesic, anti-inflammatory, and ulcerogenic activities, and does not show acute gastric effect .
    COX-2-IN-30
  • HY-170938

    Cholinesterase (ChE) Monoamine Oxidase Beta-secretase COX LOX-1 Neurological Disease
    AChE-IN-82 (compound 49) is an acetylcholinesterase (AChE) inhibitor. AChE-IN-82 inhibits eeAChE, eqBChE, hMAO-A, hMAO-B, and BACE-1 with IC50s of 0.072, 9.81, 14.52, 0.024, 2.42 μM, respectively. AChE-IN-82 inhibits COX-1, COX-2 and 5-LOX with IC50s of 60.41, 0.187, 0.18 μM, respectively. AChE-IN-82 shows an excellent neuroprotective effect by significantly reducing oxidative stress induced by H2 O2 .
    AChE-IN-82

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: